Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.23Last Year’s EPS
1.53Same Quarter Last Year
Moderate Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.Company Guidance
Growth Portfolio Outperformance
Growth portfolio revenue increased 15% year-over-year in Q4 (to $7.4B) and 17% for the full year, representing ~60% of total Q4 revenue and nearly offsetting ~ $4B decline in the legacy portfolio for the year.
Multiple High-Performing Products
Opdualag, Breyanzi, and Camzyos each exceeded $1B in full-year sales; Reblozyl exceeded $2B. Notable Q4 product growth: Breyanzi +47% (Q4), Reblozyl +21% (Q4), Camzyos +57% (Q4), Opdivo +7% (Q4), Eliquis +6% (Q4).
Strong Commercial Momentum for New Launches
Early launches showed traction: Qvantik $133M in Q4 with positive practice feedback; CoBinfy $51M in Q4 with uptake surpassing schizophrenia comparators and >100k TRx since launch.
Robust Pipeline and Near-Term Catalysts
Data-rich 2026: top-line registrational data expected for ~6 potential new products this year and over 30 meaningful launch opportunities by 2030. Key milestones include Breyanzi expansion (FDA approval in marginal zone lymphoma), multiple pemigatinib registrational studies, Break Free SSC for Zolacel, and upcoming Nablometastat oral data.
2026 Financial Guidance and EPS Outlook
2026 revenue guidance of $46.0B–$47.5B and adjusted diluted EPS guidance of $6.05–$6.35, reflecting continued growth portfolio performance and planned legacy declines.
Progress on Cost Savings and Expense Management
Delivered approximately $1B of a $2B strategic productivity initiative in 2025 with the remaining ~$1B targeted across 2026–2027. Full-year operating expenses (ex-IPR&D) decreased to $16.6B, down $1.2B vs 2024; 2026 operating expense guidance ~ $16.3B.
Balance Sheet and Cash Flow Strength
Approximately $11B in cash and marketable securities as of 12/31/2025, completed targeted $10B debt paydown ahead of schedule, and generated ~$2B operating cash flow in Q4.
Commercial Positioning and Market Access Wins
Eliquis remains a growth driver with US market share ~75% in AFib and company guidance expecting Eliquis revenue growth of 10%–15% in 2026; Opdualag and Opdivo share gains in metastatic melanoma and first-line NSCLC respectively; Opdivo subQ (Qvantik/Opdivo SC) adoption tracking to conversion target of 30%–40% of IV business by 2028.
DE:BRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:BRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 05, 2026 | €48.86 | €50.82 | +4.01% |
Oct 30, 2025 | €36.49 | €38.47 | +5.42% |
Aug 01, 2025 | €37.49 | €36.83 | -1.74% |
Apr 24, 2025 | €40.71 | €41.01 | +0.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bristol-Myers Squibb (DE:BRM) report earnings?
Bristol-Myers Squibb (DE:BRM) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Bristol-Myers Squibb (DE:BRM) earnings time?
Bristol-Myers Squibb (DE:BRM) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Bristol-Myers Squibb stock?
The P/E ratio of Bristol-Myers Squibb is N/A.
What is DE:BRM EPS forecast?
DE:BRM EPS forecast for the fiscal quarter 2026 (Q1) is 1.23.
